Core Viewpoint - Aurora Cannabis Inc. has received two licenses from Germany's Federal Institute for Drugs and Medical Devices, allowing for continued domestic cultivation and the trial of additional cultivars, positioning the company to expand its offerings in the growing German medical cannabis market [1][2][3] Group 1: Licenses and Expansion - The new licenses enable Aurora to continue domestic cultivation and to cultivate an additional approved product, enhancing its offerings to the German patient base [1][2] - Aurora plans to trial up to seven additional novel cultivars at its EU GMP facility in Leuna, Germany, under the dedicated R&D license [1][2] Group 2: Commitment and Quality - The company emphasizes its commitment to quality and compliance, which has led to the granting of additional licenses, reflecting its established leadership in the region [2][3] - Since 2021, Aurora has been cultivating approximately 1,000 kg (about 2204 lb) of medical cannabis flower annually as part of a tender agreement with BfArM [2] Group 3: Industry Impact - Aurora supports Germany's regulatory reforms, anticipating broader acceptance of medical cannabis and modern frameworks across Europe [3] - The company's expertise in developing high-quality and innovative products positions it as a leader to meet growing patient demand [3]

Investing in the stock market can be a highly rewarding pursuit. However, it also brings an oasis of risks. Some stocks possess significant financial and operational weaknesses that may lead to declines in their value. Here, the focus is on three such stocks considered for the list of stocks to sell. Each of these companies is a leader in its respective sectors. However, it faces adversities that could undermine its long-term stability and profitability. The first company’s profitability and growth are clos ...

Core Viewpoint - Aurora Cannabis Inc. is preparing for its annual general and special meeting of shareholders, emphasizing the importance of shareholder participation and outlining the company's progress and future goals [1][2][3]. Group 1: Meeting Details - The virtual meeting is scheduled for August 9, 2024, at 1:00 p.m. Eastern time, allowing shareholders to participate regardless of location [2]. - Shareholders will vote on critical matters for the company's growth, highlighting the company's efforts to stabilize and strengthen its balance sheet while reducing debt [2][3]. - The company reported that fiscal 2024 was its strongest year to date, indicating positive momentum in its operations [2]. Group 2: Company Strategy and Goals - The Board of Directors and management are focused on achieving positive free cash flow by the end of calendar 2024, with confidence in their team's capabilities to deliver shareholder value [3]. - The company aims to continue building value through stability and execution against its objectives, projecting a bright future for its operations [3]. Group 3: Shareholder Engagement - The Board recommends shareholders vote in favor of all director nominees and meeting resolutions, urging early voting before the deadline of August 7, 2024 [4]. - Shareholders are encouraged to read the management information circular for detailed voting instructions and meeting resolutions [4]. Group 4: Company Overview - Aurora Cannabis operates in the medical and consumer cannabis markets across Canada, Europe, Australia, and South America, with a diverse brand portfolio [6]. - The company is dedicated to high-quality cannabis products and innovation, positioning itself as a leader in the industry [6].

Here Are Top Marijuana Stocks For Cannabis Investors This JulyMarijuana stock investors are keeping watch for the next wave of momentum. With all that has taken place over the last several months, there is still a positive outlook for the future. People are starting to speculate on what is next for legal cannabis and investing in the sector. The DEA working on rescheduling and companies are trying to expand and keep up with consumer demands and establishing a dominant brand. This also puts people in place t ...

Core Viewpoint - The article discusses the potential for meme stocks to experience significant rallies, emphasizing the importance of identifying stocks with decent fundamentals that can benefit from speculative trading [1]. Group 1: Meme Stocks Overview - Meme stocks can experience rapid price increases, making it challenging to find good entry points [1]. - GameStop (GME) is highlighted as a meme stock to avoid due to its poor fundamentals and significant price drop from $62.8 to $23.7 [2]. - The focus is on identifying meme stocks that are undervalued and have the potential for a rally when bought on dips [1][2]. Group 2: Riot Platforms (RIOT) - Riot Platforms is considered undervalued with a forward P/E of 14, despite a 15% decline in stock price over the last 12 months [3]. - The company has a zero-debt balance sheet and a cash buffer of $1.3 billion, allowing for aggressive capacity expansion [3]. - Riot Platforms aims to increase its mining capacity from 12.5 EH/s to 31.5 EH/s by the end of the year, with a long-term goal of reaching 100 EH/s by 2027, potentially offering 5x to 10x returns in the next 24 to 36 months [4]. Group 3: Aurora Cannabis (ACB) - Aurora Cannabis is positioned for growth with the upcoming U.S. Presidential elections and favorable global regulations, including legalization in Germany [5]. - The company reported its sixth consecutive quarter of positive adjusted EBITDA and aims for positive free cash flow by December 2024 [6]. - Aurora Cannabis has been consolidating for nearly 12 months, indicating a potential for a breakout if business developments remain positive [5][6]. Group 4: Entera Bio (ENTX) - Entera Bio has seen a price correction from 52-week highs of $3.35 to $1.87, presenting a buying opportunity [7]. - The company focuses on oral delivery of peptides for treating conditions like osteoporosis, which affects 200 million women globally [7]. - Entera Bio has sufficient cash runway through Q3 of 2025, reducing the risk of immediate equity dilution [8].

Cannabis Investing 2024 Here Are 3 Canadian Marijuana Stocks For YouThe cannabis sector has experienced a large amount of growth over the years. From just a few legal states and global regions to now over 50% of the USA has a legal cannabis market. Yet even with all this progress the industry continues to face an uphill battle. Cannabis operators around the United States are dealing with several conflicting concerns.One is federal reform and having laws passed in favor of small batches and legend growers. T ...

Aurora Cannabis Inc. (NASDAQ:ACB) Q4 2024 Earnings Conference Call June 20, 2024 8:00 AM ET Company Participants Kevin Niland - Director, Strategic Finance and IR Miguel Martin - CEO Simona King - CFO Conference Call Participants Matt Bottomley - Canaccord Eric Livshits - ATB Capital Markets John Zamparo - CIBC Pablo Zuanic - Zuanic Associates Operator Greetings and welcome to the Aurora Cannabis Inc. Fourth Quarter 2024 Results Conference Call. All participants will be in a listen-only mode and a question- ...

Company Performance - Aurora Cannabis Inc. reported quarterly earnings of $0.11 per share, exceeding the Zacks Consensus Estimate of a loss of $0.18 per share, compared to a loss of $1.50 per share a year ago, indicating a significant improvement [1] - The earnings surprise for this quarter was 161.11%, while the previous quarter saw a loss of $0.20 against an expected loss of $0.10, resulting in a surprise of -100% [1] - The company generated revenues of $49.98 million for the quarter ended March 2024, which was 2.54% below the Zacks Consensus Estimate, but an increase from $47.35 million in the same quarter last year [1] Market Performance - Since the beginning of the year, Aurora Cannabis shares have increased by approximately 20.1%, outperforming the S&P 500's gain of 15% [2] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $61.12 million, and for the current fiscal year, it is -$0.32 on revenues of $230.92 million [4] - The estimate revisions trend for Aurora Cannabis is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the shares are expected to perform in line with the market in the near future [4] Industry Context - The Medical - Products industry, to which Aurora Cannabis belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [5] - Abbott, another company in the same industry, is expected to report quarterly earnings of $1.10 per share, reflecting a year-over-year change of +1.9%, with revenues projected at $10.35 billion, up 3.8% from the previous year [5]

Delivers Record Annual Adjusted EBITDA1 of $12.8 Million NASDAQ | TSX: ACB Q4 Represents the Sixth Consecutive Quarter of Positive Adjusted EBITDA1 Increased Total Quarterly Net Revenue 5% YoY to $67.4 Million, Global Medical Cannabis Net Revenue1 Grew by 20% YoY to $45.6 Million Ended the Fiscal Year with a Cash Position of ~$180 Million with Cannabis Business Debt-Free2 Re-Affirms Target of Reaching Positive Free Cash Flow1 by December 31, 2024 EDMONTON, AB, June 20, 2024 /PRNewswire/ - Aurora Cannabis ...

NASDAQ | TSX: ACB EDMONTON, AB, June 7, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2024 on Thursday, June 20, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2024 before the opening of markets th ...